Allotera Therapeutics
Develops allogeneic, off-the-shelf CAR-T cell therapies for hematological malignancies
$35MSeries C
Role not disclosedLoading investors…
Activity from announced rounds
Develops allogeneic, off-the-shelf CAR-T cell therapies for hematological malignancies
Develops a novel class of potent and precise antibody therapies to treat a broad range of cancers